Previous 10 | Next 10 |
Transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Shareholders of Nuvation Bio and AnHeart Therapeutics immediately prior to close now own approximately 67% and 33%, respectively, of Nuvation Bio on a full...
2024-03-31 10:00:00 ET Summary Nuvation Bio has acquired an advanced pipeline candidate, taletrectinib, leading to a surge in market cap approaching $1 billion. Taletrectinib has shown promising clinical activity in treating ROS1-positive non-small cell lung cancer and has Breakth...
2024-03-31 04:50:00 ET Summary South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770M. AnHeart Therapeutics, a New York-Hangzhou biopharma, will become part of Nuvation Bio (NYSE: NUVB) of New Yo...
Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches Pending acquisition of AnHeart Therapeutics and expanded leadership strongly positions Nuvation Bio to potentially become a commercial organization...
2024-03-27 08:52:30 ET More on Nuvation Bio BTIG upgrades Nuvation to buy, cites AnHeart acquisition Nuvation Bio falls after AnHeart Therapeutics acquisition news Seeking Alpha’s Quant Rating on Nuvation Bio Historical earnings data for Nuvation Bio ...
2024-03-27 08:24:20 ET More on premarket gainers & stock Veritone: Not An AI Stock To Bank On Veritone, Inc. (VERI) Q4 2023 Earnings Call Transcript Mesoblast Limited (MESO) Q2 2024 Earnings Call Transcript Mesoblast gains as FDA backs regulatory plans fo...
2024-03-27 05:15:02 ET Jefferies analyst issues BUY recommendation for NUVB on March 27, 2024 12:40AM ET. The previous analyst recommendation was Hold. NUVB was trading at $2.88 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...
2024-03-26 13:37:15 ET More on Nuvation Bio Nuvation Bio falls after AnHeart Therapeutics acquisition news Seeking Alpha’s Quant Rating on Nuvation Bio Historical earnings data for Nuvation Bio Financial information for Nuvation Bio Read the ...
2024-03-26 12:55:48 ET More on Mid-day movers & stocks. Veritone: Not An AI Stock To Bank On Veritone, Inc. (VERI) Q4 2023 Earnings Call Transcript Check-Cap jumps on Nobul AI business combination Veritone Non-GAAP EPS of -$0.16 in-line, revenue of $34.2M...
2024-03-26 07:00:03 ET Kaveri Pohlman from BTIG issued a price target of $5.00 for NUVB on 2024-03-26 05:37:00. The adjusted price target was set to $5.00. At the time of the announcement, NUVB was trading at $2.25. The overall price target consensus is at $8.00 with hig...
News, Short Squeeze, Breakout and More Instantly...
Nuvation Bio Inc. Class A Company Name:
NUVB Stock Symbol:
NYSE Market:
Nuvation Bio Inc. Class A Website:
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at t...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced today that David Hung, M.D., Founder, President, and Chief Executive Officer of Nu...
Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at...